

Elena Di Gennaro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/585664/publications.pdf>

Version: 2024-02-01

44
papers

1,852
citations

236612

25
h-index

253896

43
g-index

45
all docs

45
docs citations

45
times ranked

3197
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. <i>Journal of Cellular Physiology</i> , 2011, 226, 2378-2390. | 2.0 | 139 |
| 2 | Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. <i>Journal of Cellular Physiology</i> , 2003, 195, 139-150. | 2.0 | 127 |
| 3 | New Perspective for an Old Antidiabetic Drug: Metformin as Anticancer Agent. <i>Cancer Treatment and Research</i> , 2014, 159, 355-376. | 0.2 | 119 |
| 4 | Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 3075-3087. | 1.9 | 104 |
| 5 | Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients. <i>Journal of Pathology</i> , 2004, 204, 317-325. | 2.1 | 93 |
| 6 | Synergistic Antitumor Activity of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib and IFN- α in Head and Neck Cancer Cells In vitro and In vivo. <i>Clinical Cancer Research</i> , 2006, 12, 617-625. | 3.2 | 88 |
| 7 | Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway. <i>Free Radical Biology and Medicine</i> , 2015, 89, 287-299. | 1.3 | 73 |
| 8 | EGF activates an inducible survival response via the RAS-> Erk-1/2 pathway to counteract interferon- α -mediated apoptosis in epidermoid cancer cells. <i>Cell Death and Differentiation</i> , 2003, 10, 218-229. | 5.0 | 67 |
| 9 | Valproic acid potentiates the anticancer activity of capecitabine <i>in vitro</i> and <i>in vivo</i> in breast cancer models via induction of thymidine phosphorylase expression. <i>Oncotarget</i> , 2016, 7, 7715-7731. | 0.8 | 67 |
| 10 | Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or Raltitrexed. <i>Cancer Biology and Therapy</i> , 2009, 8, 782-791. | 1.5 | 65 |
| 11 | Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial. <i>BMC Cancer</i> , 2016, 16, 918. | 1.1 | 60 |
| 12 | Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells. <i>Cell Death and Disease</i> , 2013, 4, e641-e641. | 2.7 | 57 |
| 13 | Tissue transglutaminase: a new target to reverse cancer drug resistance. <i>Amino Acids</i> , 2013, 44, 63-72. | 1.2 | 52 |
| 14 | Endothelial progenitor cells, defined by the simultaneous surface expression of VEGFR 2 and CD 133 , are not detectable in healthy peripheral and cord blood. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2016, 89, 259-270. | 1.1 | 51 |
| 15 | Histone Deacetylase Inhibitors: A New Wave of Molecular Targeted Anticancer Agents. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2007, 2, 119-134. | 0.8 | 51 |
| 16 | Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways. <i>Cell Death and Disease</i> , 2013, 4, e878-e878. | 2.7 | 50 |
| 17 | Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase. <i>British Journal of Cancer</i> , 2010, 103, 1680-1691. | 2.9 | 42 |
| 18 | Caveolin-1 overexpression is associated with simultaneous abnormal expression of the E-cadherin/ β -catenins complex and multiple erbb receptors and with lymph nodes metastasis in head and neck squamous cell carcinomas. <i>Journal of Cellular Physiology</i> , 2012, 227, 3344-3353. | 2.0 | 40 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | A standardized flow cytometry network study for the assessment of circulating endothelial cell physiological ranges. <i>Scientific Reports</i> , 2018, 8, 5823. | 1.6 | 38 |
| 20 | Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid - short RadioTherapy - rectum) Tj ETQq0 0 OrgBT /Overlock 10 Tf | 1.0 | 10 |
| 21 | Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma. <i>Cell Cycle</i> , 2014, 13, 652-665. | 1.3 | 36 |
| 22 | Implication for Cancer Stem Cells in Solid Cancer Chemo-Resistance: Promising Therapeutic Strategies Based on the Use of HDAC Inhibitors.. <i>Journal of Clinical Medicine</i> , 2019, 8, 912. | 1.0 | 36 |
| 23 | Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 177. | 3.5 | 33 |
| 24 | Multiple-Target Drugs: Inhibitors of Heat Shock Protein 90 and of Histone Deacetylase. <i>Current Drug Targets</i> , 2005, 6, 337-351. | 1.0 | 33 |
| 25 | Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 113-129. | 1.0 | 30 |
| 26 | Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 213. | 3.5 | 26 |
| 27 | Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 732. | 1.8 | 22 |
| 28 | Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hepâ€2 cancer cells. <i>Proteomics</i> , 2011, 11, 3725-3742. | 1.3 | 21 |
| 29 | Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression. <i>Oncotarget</i> , 2016, 7, 19559-19574. | 0.8 | 20 |
| 30 | HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 83. | 3.5 | 19 |
| 31 | Restoring p53 Function in Cancer: Novel Therapeutic Approaches for Applying the Brakes to Tumorigenesis. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2010, 5, 1-13. | 0.8 | 18 |
| 32 | A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization) Tj ETQq0 0 OrgBT /Overlock 10 Tf | 1.0 | 10 |
| 33 | Vorinostat Potentiates 5-Fluorouracil/Cisplatin Combination by Inhibiting Chemotherapy-Induced EGFR Nuclear Translocation and Increasing Cisplatin Uptake. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1405-1417. | 1.9 | 18 |
| 34 | Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2021, 4, e2118475. | 2.8 | 16 |
| 35 | Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells. <i>Anti-Cancer Drugs</i> , 2007, 18, 781-791. | 0.7 | 15 |
| 36 | Synthesis of 1-naphtylpiperazine derivatives as serotonergic ligands and their evaluation as antiproliferative agents. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 2206-2216. | 2.6 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Synthesis and Evaluation of the Antitumor Properties of a Small Collection of Pt ^{II} Complexes with 7-Deazaadenosine as Scaffold. <i>European Journal of Organic Chemistry</i> , 2017, 2017, 4935-4947. | 1.2 | 10 |
| 38 | Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with <i>RAS</i> -mutated metastatic colorectal cancer: the REVOLUTION study protocol. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092958. | 1.4 | 10 |
| 39 | Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat. <i>Amino Acids</i> , 2017, 49, 517-528. | 1.2 | 9 |
| 40 | Cisplatin, raltitrexed, levofoinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: A phase II trial of the Southern Italy Cooperative Oncology Group (SICOG). <i>Annals of Oncology</i> , 2000, 11, 575-580. | 0.6 | 8 |
| 41 | HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer. <i>Molecular Oncology</i> , 2021, 15, 1005-1023. | 2.1 | 8 |
| 42 | Synthesis and Evaluation of the Antiproliferative Properties of a Tethered Tubercidin-Platinum(II) Complex. <i>European Journal of Organic Chemistry</i> , 2015, 2015, 7550-7556. | 1.2 | 6 |
| 43 | Up-regulated EGF receptors undergo to rapid internalization and ubiquitin-dependent degradation in human cancer cells exposed to 8-Cl-cAMP. <i>FEBS Letters</i> , 1999, 447, 203-208. | 1.3 | 4 |
| 44 | Epigenetic Approaches to Overcome Fluoropyrimidines Resistance in Solid Tumors. <i>Cancers</i> , 2022, 14, 695. | 1.7 | 3 |